Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.87 |
| ▸ | CCR1 | P32246 | 11/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.73 |
| ▸ | DRD4 | P21917 | 3/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.73 |
| ▸ | HRH2 | P25021 | 2/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.73 |
| ▸ | CCR3 | P51677 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14580936 | 0.93 | OPRM1 (1.00) | OPRM1CCR1ADRA2ADRD4SLC6A4 | |
| SCHEMBL2310814 | 0.85 | OPRM1 (0.85) | OPRM1CCR1ADRA2ADRD4SLC6A4 | |
| SCHEMBL12387698 | 0.85 | OPRM1 (0.85) | OPRM1CCR1ADRA2ADRD4SLC6A4 | |
| SCHEMBL8901930 | 0.85 | CCR1 (0.74) | OPRM1CCR1ADRA2ADRD4SLC6A4 | |
| SCHEMBL2313168 | 0.84 | OPRM1 (1.00) | OPRM1CCR1ADRA2ADRD4SLC6A4 | |
| SCHEMBL12387673 | 0.84 | OPRM1 (1.00) | OPRM1CCR1ADRA2ADRD4SLC6A4 | |
| SCHEMBL8891231 | 0.84 | CCR1 (1.00) | OPRM1CCR1CCR3 | |
| Hydrochloric Acid SCHEMBL7170114 | 0.84 | OPRM1 (0.98) | OPRM1CCR1ADRA2ADRD4SLC6A4 | |
| SCHEMBL9108847 | 0.84 | CCR1 (0.82) | OPRM1CCR1CCR3 | |
| SCHEMBL21538258 | 0.83 | OPRM1 (0.82) | OPRM1CCR1ADRA2ADRD4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2648754-A2 | METHODS OF INHIBITING METASTASIS FROM CANCER | Philadelphia Health and Education Corporation D/B/A (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2012078633-A2 | METHODS OF INHIBITING METASTASIS FROM CANCER | PHILADELPHIA HEALTH AND EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICENE (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | OPRM1 703/4885CCR1 15/4885ADRA2A 1128/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | OPRM1 703/4885CCR1 15/4885ADRA2A 1128/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | OPRM1 591/4885CCR1 15/4885ADRA2A 894/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | OPRM1 703/4885CCR1 15/4885ADRA2A 1128/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | OPRM1 703/4885CCR1 15/4885ADRA2A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.